P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMET... by Carlos Jimenez-Vicente, Francesca Guijarro, Monica Lopez-Guerra, Ares Guardia-Torrelles, Alexandra Martínez Roca, Alex Bataller, Daniel Esteban, Albert Cortés, Inés Zugasti, Daniel Munarriz, Dolors Colomer, Marina Diaz-Beya, Jordi Esteve

Get full text

PB1846: MANAGEMENT OF PATIENTS TREATED WITH VENETOCLAX WITH HYPOMETHYLATING AGENTS: LONG-TERM INCIDENCE OF CYTOPENIAS AND INFECTIONS by Ares Guardia-Torrelles, Carlos Jimenez-Vicente, Alexandra Martínez Roca, Sandra Castaño-Díez, Helena Brillembourg, Francesca Guijarro, Àlex Bataller, Daniel Esteban, Albert Cortés, Inés Zugasti, Daniel Munarriz, Marina Diaz-Beya, Jordi Esteve, Beatriz Merchan

Get full text

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia by Carlos Jiménez-Vicente, Iago Arribas, Helena Pomares, Guillermo Ramil, Sandra Castaño-Diez, Amanda Isabel Pérez-Valencia, Antonella Luciana Sturla, Mònica López-Guerra, Alexandra Martinez-Roca, Inés Zugasti, Francesca Guijarro, Albert Cortés-Bullich, Beatriz Merchán, Ana Triguero, Inés Monge, Albert Tuca, Guadalupe Oñate, Ana Garrido, Jorge Sierra, Montserrat Arnan, Jordi Esteve, Marina Díaz-Beyá, Spanish CETLAM Group

Get full text